- Home
- DOMO vs IMMP Comparison
DOMO vs IMMP Comparison
Compare DOMO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- IMMP
- Stock Information
- Founded
- DOMO 2010
- IMMP 1987
- Country
- DOMO United States
- IMMP Australia
- Employees
- DOMO N/A
- IMMP N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- DOMO Technology
- IMMP Health Care
- Exchange
- DOMO Nasdaq
- IMMP Nasdaq
- Market Cap
- DOMO 336.9M
- IMMP 304.0M
- IPO Year
- DOMO 2018
- IMMP N/A
- Fundamental
- Price
- DOMO $8.16
- IMMP $1.92
- Analyst Decision
- DOMO Hold
- IMMP Buy
- Analyst Count
- DOMO 6
- IMMP 2
- Target Price
- DOMO $10.25
- IMMP $8.50
- AVG Volume (30 Days)
- DOMO 352.7K
- IMMP 72.2K
- Earning Date
- DOMO 03-06-2025
- IMMP 03-03-2025
- Dividend Yield
- DOMO N/A
- IMMP N/A
- EPS Growth
- DOMO N/A
- IMMP N/A
- EPS
- DOMO N/A
- IMMP N/A
- Revenue
- DOMO $318,458,000.00
- IMMP $2,563,302.00
- Revenue This Year
- DOMO $0.94
- IMMP N/A
- Revenue Next Year
- DOMO N/A
- IMMP $47.79
- P/E Ratio
- DOMO N/A
- IMMP N/A
- Revenue Growth
- DOMO 0.01
- IMMP 9.59
- 52 Week Low
- DOMO $6.11
- IMMP $1.66
- 52 Week High
- DOMO $11.87
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- DOMO 46.98
- IMMP 43.56
- Support Level
- DOMO $8.25
- IMMP $1.94
- Resistance Level
- DOMO $9.25
- IMMP $2.08
- Average True Range (ATR)
- DOMO 0.48
- IMMP 0.08
- MACD
- DOMO -0.06
- IMMP -0.00
- Stochastic Oscillator
- DOMO 3.52
- IMMP 20.00
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.